Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MALVERN, Pa., Feb. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering. The offering is expected to close on or about February 10, 2021, subject to the satisfaction of customary closing conditions.

Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 61.54% on Friday, February 5. This is why it happened.

OCGN Stock Price Increases 61.54%: Why It Happened

Analysts are growing more bullish on the biotech's growth prospects.

Why Ocugen Stock Skyrocketed Today

With ink drying on its deal with Bharat Biotech, Covid-19 vaccine stock Occugen ended the week on a strong bullish note. The post OCGN Stock: What to Know as Ocugen Soars Today appeared first on InvestorPlace.

OCGN Stock: What to Know as Ocugen Soars Today

Investors are reacting positively to an analyst's upgrade.

Why Ocugen Stock Is Soaring Today

eBay

Eastman Kodak

PayPal

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Here's Why eBay, PayPal, Ocugen And Kodak Are Moving

OCGN stock is falling a day after Ocugen announced its plans to commercialize a Covid-19 vaccine. Here's what you need to know.

OCGN Stock: Why Vaccine Play Ocugen Is Plunging Today

The company's stock is losing altitude despite bullish sentiments from a Wall Street analyst.

Why Ocugen Stock Is Dropping Today

BioCryst Pharmaceuticals

Voyager Therapeutics

Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical trials of the NBIb1-817. Voyager planned to support Neurocrine by sponsoring its trial.

Why BioCryst, Ocugen And Voyager Therapeutics Are Moving Today

OCGN stock has tempted many speculators recently with its high-flying acrobatics. But you'll want to read the label on Ocugen very carefully before even thinking about pulling the trigger.

Read the Label Carefully Before Gambling on Ocugen Stock

The biotech struck an agreement to bring a promising coronavirus vaccine candidate to the U.S.

Why Ocugen Stock Soared Today

The stock price of Ocugen Inc (NASDAQ: OCGN) is trading at over 70% today. This is why it happened.

OCGN Stock Price Increases Over 70%: Why It Happened

Ocugen Inc (NASDAQ: OCGN) shares were advancing sharply Tuesday on above-average volume. Ocugen, a gene therapy company, said it has executed a definitive agreement with India's Bharat Biotech to co-develop, supply and commercialize the latter's Covaxin in the U.S.

Ocugen Spikes On US COVID-19 Vaccine Manufacturing Deal With Bharat Biotech

No one wants to be the bearer of bad news, but we must acknowledge that the vertical move in OCGN stock is turning out to be unsustainable. The post The Vaccine Deal Boost Can't Keep Ocugen Stock Afloat appeared first on InvestorPlace.

The Vaccine Deal Boost Can't Keep Ocugen Stock Afloat

MALVERN, Pa. and HYDERABAD, India, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, and Bharat Biotech, a global leader in vaccine innovation, today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech's COVAXIN™, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.

Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market

OCGN stock has gone crazy amid a partnership to develop a Covid-19 vaccine. The problem is there's little evidence it will actually work.

Don't Get Suckered Into Ocugen Stock

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) complied with federal securities laws. On January 12, 2021, Ocugen announced the cancellation of a Company stockholder meeting for the following day and plans to re-evaluate the details of a proposed increase in the number of shares of common stock "in light of the recent potential addition of COVAXIN™ to its...

SHAREHOLDER ALERT: Investigation of Ocugen Announced by Holzer & Holzer, LLC

Ocugen is hanging on by a thread with its latest Indian biotech deal. OCGN stock looks to be a highly speculative play with a negative expected return.

Ocugen Is Hanging On By a Thread With Its Latest Indian Biotech Deal

Celebrating Ocugen's value-added collaboration to develop a potentially lifesaving vaccine is fine, but OCGN stock might be too pricey now. The post Ocugen Stock Looks Overinflated appeared first on InvestorPlace.

Ocugen Stock Looks Overinflated

MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced it has determined to withdraw from stockholder consideration Item 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on October 30, 2020, with respect to an increase in the number of shares of common stock authorized for issuance under the Company's Sixth Amended and Restated Certificate of Incorporation. As a result, the Company has determined to cancel the reconvening of its annual meeting of stockholders, which was previously adjourned solely with respect to Item 2 to 11:00 a.m. Eastern Time on January 13, 2021. All other items set forth in the Company's Definitive Proxy Statement were submitted to stockholder vote at the Company's annual meeting of stockholders on December 23, 2020. The Company plans to re-evaluate the details of Item 2 in light of the recent potential addition of COVAXIN™ to its pipeline as well as its compliance with Nasdaq's Listing Rule 5550(a)(2).

Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021

Chesapeake Energy

Genius Brands

Hertz

Remark Hlds

StoneMor Partners

VBI Vaccines

XpresSpa Group

With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GNUS) Hertz Global Holdings (OTCMKTS:HTZGQ) Remark Holdings (NASDAQ:MARK) Ocugen (NASDAQ:OCGN) StoneMor (NYSE:STON) VBI Vaccines (NASDAQ:VBIV) XspresSpa (NASDAQ:XSPA) The post 8 Penny Stocks to Avoid in 2021 appeared first on InvestorPlace.

8 Penny Stocks to Avoid in 2021

MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2).

Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule

Shares of Ocugen (NASDAQ: OCGN) increased by 67.76% as it went from a previous close of $1.83 to $3.07 per share today. This is why it happened.

OCGN Stock Price Increases 67.76%: Why It Happened

Investors are excited about big news for Ocugen's Indian partner.

Why Ocugen Stock Is Crushing It Today

Ocugen shares surged after its Indian development partner got emergency-use authorization for its Covid-19 vaccine. OCGN stock remains one to watch as new virus waves strike.

News for Ocugen, Inc. Stock (OCGN)